These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21976975)

  • 21. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
    Yang C; Cao H; Liu N; Xu K; Ding M; Mao LJ
    Drug Des Devel Ther; 2016; 10():3755-3761. PubMed ID: 27895465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
    Olszewska-Słonina DM; Styczyńisk J; Drewa TA; Olszewski KJ; Czajkowski R
    Acta Pol Pharm; 2005; 62(6):473-83. PubMed ID: 16583988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
    Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
    Melanoma Res; 2002 Aug; 12(4):335-42. PubMed ID: 12170182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD47-mediated DTIC-loaded chitosan oligosaccharide-grafted nGO for synergistic chemo-photothermal therapy against malignant melanoma.
    Zhan X; Teng W; Sun K; He J; Yang J; Tian J; Huang X; Zhou L; Zhou C
    Mater Sci Eng C Mater Biol Appl; 2021 Apr; 123():112014. PubMed ID: 33812633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
    Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
    Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.
    Finnberg NK; Gokare P; Navaraj A; Lang Kuhs KA; Cerniglia G; Yagita H; Takeda K; Motoyama N; El-Deiry WS
    Cancer Res; 2016 Feb; 76(3):700-12. PubMed ID: 26609054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
    Kiebert GM; Jonas DL; Middleton MR
    Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
    Singh S; Davis R; Alamanda V; Pireddu R; Pernazza D; Sebti S; Lawrence N; Chellappan S
    Mol Cancer Ther; 2010 Dec; 9(12):3330-41. PubMed ID: 21139044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
    Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
    Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
    Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
    J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of iontophoresis on dacarbazine cutaneous delivery for melanoma topical treatment.
    Cardoso CO; Silva-Carvalho AE; Mota IS; Lopez RFV; Cunha-Filho M; Saldanha-Araújo F; Gratieri T; Gelfuso GM
    Int J Pharm; 2024 Nov; 665():124730. PubMed ID: 39299356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.
    Kiyohara E; Tamai K; Katayama I; Kaneda Y
    Gene Ther; 2012 Jul; 19(7):734-41. PubMed ID: 21900962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.
    Kawahara T; Toso C; Yamaguchi K; Cader S; Douglas DN; Nourbakhsh M; Lewis JT; Churchill TA; Yagita H; Kneteman NM
    Liver Int; 2013 Oct; 33(9):1441-8. PubMed ID: 23895107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
    Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
    Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.